Concepedia

Author

Grit Andersen

Profil Institute for Metabolic ResearchORCID

Also Known As

G Andersen, G. Andersen, G.H. Andersen, GRIT ANDERSEN, Grit Andersen

45

Publications

455

Citations

10

H-Index

5

Concepts

All Affiliations

Profil Institute for Metabolic ResearchAdocia (France)
GA

About

Grit Andersen is an author at Profil Institute for Metabolic Research specializing in medicine, animal physiology, and physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

56

2

Pharmacology

1

1

56

3

Physiology

1

1

56

4

Animal Physiology

1

1

56

5

Neuropharmacology

1

1

56

Grit Andersen

×

10

Publications

409

Citations

10

H-Index

YearCitations

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Anne Flint, Grit Andersen, Paul Hockings,

Alimentary Pharmacology & Therapeutics

2021

193

The utilization of Schardinger dextrins by the rat

Grit Andersen, Frederick M. Robbins, F.J. Domingues,

Toxicology and Applied Pharmacology

1963

56

Ultra‐rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14‐day crossover treatment study in people with type 1 diabetes

Grit Andersen, Grégory Meiffren, Daniela Lamers,

Diabetes Obesity and Metabolism

2018

37

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Jennifer Leohr, Mary Anne Dellva, David E. Coutant,

Clinical Pharmacokinetics

2020

31

ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

Grit Andersen, Grégory Meiffren, Susanne Famulla,

Diabetes Obesity and Metabolism

2020

27

Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: <scp>A</scp> n exploratory mechanistic study

Thomas Först, Alexander Falk, Grit Andersen,

Diabetes Obesity and Metabolism

2016

18

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers

Viktoria Moschetti, Maria Kim, Michael Sand,

European Neuropsychopharmacology

2018

13

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

L. Bergougnan, Grit Andersen, Leona Plum‐Mörschel,

British Journal of Clinical Pharmacology

2020

13

Pharmacokinetic and pharmacodynamic bioequivalence of Gan &amp; Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with <scp>EU</scp> ‐ und <scp>US‐sourced</scp> reference insulins

Wei Chen, Jia Lu, Leona Plum‐Mörschel,

Diabetes Obesity and Metabolism

2023

11

A co‐formulation of pramlintide and insulin <scp>A21G</scp> ( <scp>ADO09</scp> ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes

Grit Andersen, Rosy Eloy, Susanne Famulla,

Diabetes Obesity and Metabolism

2023

10

Page 1